Covered recipient · General Payments record
BRIAN R BRANCHFORD
Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology
General Payments · PY2018–2024
$56,248.15
- Reported across 79 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,437.50 | 2 |
| Travel and Lodging | $2,374.85 | 6 |
| Food and Beverage | $1,313.66 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $9,331.95 | 6 |
| CSL Behring | $1,477.03 | 15 |
| Kedrion Biopharma, Inc. | $178.48 | 2 |
| Genentech USA, Inc. | $86.66 | 1 |
| PFIZER INC. | $28.32 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $23.57 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (26)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20182019202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $23.57 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086189654 | CMS |
| CSL Behring | $110.11 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611221 | CMS |
| CSL Behring | $76.80 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611223 | CMS |
| CSL Behring | $23.77 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611225 | CMS |
| CSL Behring | $67.67 | 04/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611227 | CMS |
| CSL Behring | $32.86 | 04/28/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134611229 | CMS |
| CSL Behring | $687.71 | 04/28/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134611231 | CMS |
| CSL Behring | $46.31 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611233 | CMS |
| CSL Behring | $120.60 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611235 | CMS |
| CSL Behring | $25.28 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611237 | CMS |
| CSL Behring | $10.78 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611239 | CMS |
| CSL Behring | $8.46 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611241 | CMS |
| CSL Behring | $109.09 | 04/29/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1134611243 | CMS |
| CSL Behring | $62.21 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611245 | CMS |
| CSL Behring | $72.75 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611247 | CMS |
| CSL Behring | $22.63 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134611249 | CMS |
| Genentech USA, Inc. | $86.66 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132982583 | CMS |
| Kedrion Biopharma, Inc. | $134.82 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125861085 | CMS |
| Kedrion Biopharma, Inc. | $43.66 | 12/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125861087 | CMS |
| Novo Nordisk Inc | $1,190.00 | 08/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097733672 | CMS |
| Novo Nordisk Inc | $757.95 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096594316 | CMS |
| Novo Nordisk Inc | $420.44 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096918042 | CMS |
| Novo Nordisk Inc | $6,247.50 | 08/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097070841 | CMS |
| Novo Nordisk Inc | $349.26 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097497719 | CMS |
| Novo Nordisk Inc | $366.80 | 08/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1097693515 | CMS |
| PFIZER INC. | $28.32 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131595480 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.